Shulei Zhu

Dr. Shulei Zhu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
QGQingsong Guo
Qingsong Guo
BGBei Gao
Bei Gao
RSRuiwen Song
Ruiwen Song
WLWeinan Li
Weinan Li
SZShulei Zhu
Shulei Zhu
TYTong Yang
Tong Yang
Delta-like ligand 3 (DLL3) is overexpressed in small cell lung cancer (SCLC) and has been considered an attractive target for SCLC therapy. Rovalpituzumab tesirine was the first DLL3-targeted antibody–drug conjugate (ADC) to enter clinical studies. However, serious adverse events limited progress in the treatment of SCLC with rovalpituzumab tesirine. In this study, we developed a novel DLL3-targeted ADC, FZ-AD005, by using DXd with potent cytotoxicity and a relatively better safety profile to maximize the therapeutic index. FZ-AD005 was generated by a novel anti-DLL3 antibody, FZ-A038, and a valine–alanine (Val–Ala) dipeptide linker to conjugate DXd. Moreover, Fc-silencing technology was introduced in FZ-AD005 to avoid off-target toxicity mediated by FcγRs and showed negligible Fc-mediated effector functions in vitro. In preclinical evaluation, FZ-AD005 exhibited DLL3-specific binding and demonstrated efficient internalization, bystander killing, and excellent in vivo antitumor activities in cell line–derived xenograft and patient-derived xenograft models. FZ-AD005 was stable in circulation with acceptable pharmacokinetic profiles in cynomolgus monkeys. FZ-AD005 was well tolerated in rats and monkeys. The safety profile of FZ-AD005 was favorable, and the highest nonseverely toxic dose was 30 mg/kg in cynomolgus monkeys. In conclusion, FZ-AD005 has the potential to be a superior DLL3-targeted ADC with a wide therapeutic window and is expected to provide clinical benefits for the treatment of patients with SCLC.

16 December 2022 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MDMengyuan Ding
Mengyuan Ding
YSYingying Shao
Yingying Shao
DSDanwen Sun
Danwen Sun
SMSuorina Meng
Suorina Meng
YZYi Zang
Yi Zang
SZShulei Zhu
Shulei Zhu

29 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
YLYingxin Lu
Yingxin Lu
DSDanwen Sun
Danwen Sun
DXDonghuai Xiao
Donghuai Xiao
YSYing-Ying Shao
Ying-Ying Shao
MSMingbo Su
Mingbo Su
WLWei Lu Lu
Wei Lu Lu
Histone deacetylases (HDACs) play important roles in cell growth, cell differentiation, cell apoptosis, and many other cellular processes. The inhibition of different classes of HDACs has been shown to be closely related to the therapy of cancers and other diseases. In this study, a series of novel CRBN-recruiting HDAC PROTACs were designed and synthesized by linking hydroxamic acid and benzamide with lenalidomide, pomalidomide, and CC-220 through linkers of different lengths and types. One of these PROTACs, denoted 21a, with a new benzyl alcohol linker, exhibited comparably excellent HDAC inhibition activity on different HDAC classes, acceptable degradative activity, and even better in vitro anti-proliferative activities on the MM.1S cell line compared with SAHA. Moreover, we report for the first time the benzyl alcohol linker, which could also offer the potential to be used to develop more types of potent PROTACs for targeting more proteins of interest (POI).

11 April 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
XJXing Jiang
Xing Jiang
LZLingyi Zhu
Lingyi Zhu
QWQingyu Wei
Qingyu Wei
WLWei Lu
Wei Lu
JiaHui YuJiaHui Yu
JiaHui Yu
SZShulei Zhu
Shulei Zhu

14 April 2024 in Bioorganic Chemistry
Verified
Journal Article
Closed access
YLYingxin Lu
Yingxin Lu
YHYing Huang
Ying Huang
JJJiyu Jin
Jiyu Jin
JYJiahui Yu
Jiahui Yu
WLWei Lu Lu
Wei Lu Lu
SZShulei Zhu
Shulei Zhu

15 March 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XLXiaomei Li
Xiaomei Li
MLMinmin Liu
Minmin Liu
HWHuijing Wang
Huijing Wang
JMJialuo Mao
Jialuo Mao
XZXiangying Zhai
Xiangying Zhai
SZShulei Zhu
Shulei Zhu